Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...
Lightbridge’s fuel technology boosts US nuclear energy’s future. See why LTBR stock is gaining attention despite competition ...
Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback